KR102285401B1 - 암 및 피부 병변 치료 - Google Patents
암 및 피부 병변 치료 Download PDFInfo
- Publication number
- KR102285401B1 KR102285401B1 KR1020177013441A KR20177013441A KR102285401B1 KR 102285401 B1 KR102285401 B1 KR 102285401B1 KR 1020177013441 A KR1020177013441 A KR 1020177013441A KR 20177013441 A KR20177013441 A KR 20177013441A KR 102285401 B1 KR102285401 B1 KR 102285401B1
- Authority
- KR
- South Korea
- Prior art keywords
- hpv
- vaccine
- dose
- administration
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 85
- 201000011510 cancer Diseases 0.000 title claims description 36
- 206010040882 skin lesion Diseases 0.000 title description 8
- 231100000444 skin lesion Toxicity 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 84
- 229960002566 papillomavirus vaccine Drugs 0.000 claims abstract description 53
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 25
- 206010004146 Basal cell carcinoma Diseases 0.000 claims abstract description 21
- 229960005486 vaccine Drugs 0.000 claims description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 29
- 229940124551 recombinant vaccine Drugs 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 12
- 229940031351 tetravalent vaccine Drugs 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 230000003902 lesion Effects 0.000 abstract description 51
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 33
- 201000000849 skin cancer Diseases 0.000 abstract description 27
- 241000701806 Human papillomavirus Species 0.000 description 82
- 229940124897 Gardasil Drugs 0.000 description 13
- 201000001441 melanoma Diseases 0.000 description 12
- 238000011200 topical administration Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 201000010153 skin papilloma Diseases 0.000 description 10
- 206010059313 Anogenital warts Diseases 0.000 description 9
- 208000000260 Warts Diseases 0.000 description 9
- 229940021993 prophylactic vaccine Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
- 201000004201 anogenital venereal wart Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 | |
| US62/068,332 | 2014-10-24 | ||
| PCT/US2015/057150 WO2016065281A1 (en) | 2014-10-24 | 2015-10-23 | Cancer and skin lesion treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170072279A KR20170072279A (ko) | 2017-06-26 |
| KR102285401B1 true KR102285401B1 (ko) | 2021-08-02 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177013441A Active KR102285401B1 (ko) | 2014-10-24 | 2015-10-23 | 암 및 피부 병변 치료 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (enExample) |
| EP (1) | EP3209676A4 (enExample) |
| JP (1) | JP6663438B2 (enExample) |
| KR (1) | KR102285401B1 (enExample) |
| CN (1) | CN107001430A (enExample) |
| AU (1) | AU2015335652B2 (enExample) |
| BR (1) | BR112017008280A2 (enExample) |
| CA (1) | CA2965498A1 (enExample) |
| CL (1) | CL2017001008A1 (enExample) |
| IL (1) | IL251825B2 (enExample) |
| MX (1) | MX395186B (enExample) |
| MY (1) | MY195018A (enExample) |
| PH (1) | PH12017500754A1 (enExample) |
| SG (1) | SG11201703262UA (enExample) |
| WO (1) | WO2016065281A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017223970B2 (en) * | 2016-02-27 | 2022-01-27 | Hpvvax, Llc | Method and composition for treating cancer or skin lesion using a vaccine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE354662T1 (de) * | 2001-03-23 | 2007-03-15 | Deutsches Krebsforsch | Modifizierte hpv e6- und e7-gene und -proteine als impfstoff |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| ATE503492T1 (de) | 2002-12-20 | 2011-04-15 | Glaxosmithkline Biolog Sa | Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
| MXPA06014515A (es) * | 2004-06-16 | 2007-03-23 | Glaxosmithkline Biolog Sa | Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52. |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| EP2129394B1 (en) * | 2007-03-09 | 2012-06-20 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| EP2416798B1 (en) * | 2009-04-10 | 2017-09-20 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| CN102481378A (zh) * | 2009-04-13 | 2012-05-30 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| WO2010147268A1 (ko) | 2009-06-19 | 2010-12-23 | 아이진 주식회사 | 자궁경부암 백신 |
| MX2011013744A (es) * | 2009-06-25 | 2012-09-28 | Glaxosmithkline Biolog Sa | Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv. |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| WO2012170384A1 (en) * | 2011-06-06 | 2012-12-13 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| CA2866582A1 (en) * | 2012-03-18 | 2013-09-26 | Brigitte Desiree Alberte Colau | Method of vaccination against human papillomavirus |
| US20150086587A1 (en) * | 2012-03-28 | 2015-03-26 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9974849B2 (en) | 2013-10-13 | 2018-05-22 | Bioventures, Llc | Human Papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
-
2017
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
Non-Patent Citations (3)
| Title |
|---|
| Clinics in Dermatology, 제32권, 제2호, 248-252면(2014.03.01.) |
| Journal of the Americal Academy of Dermatology, 제67권 제2호, e73-e74(2012) |
| PLoS pathogen, e1003924 (2014.02.01.) |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201703262UA (en) | 2017-05-30 |
| CL2017001008A1 (es) | 2017-11-24 |
| PH12017500754A1 (en) | 2017-10-30 |
| CA2965498A1 (en) | 2016-04-28 |
| CN107001430A (zh) | 2017-08-01 |
| AU2015335652B2 (en) | 2020-07-02 |
| MX2017005418A (es) | 2017-11-30 |
| BR112017008280A2 (pt) | 2018-01-02 |
| AU2015335652A1 (en) | 2017-05-25 |
| IL251825A0 (en) | 2017-06-29 |
| IL251825B1 (en) | 2023-05-01 |
| US20160114023A1 (en) | 2016-04-28 |
| IL251825B2 (en) | 2023-09-01 |
| WO2016065281A1 (en) | 2016-04-28 |
| EP3209676A4 (en) | 2018-03-28 |
| JP6663438B2 (ja) | 2020-03-11 |
| JP2017531699A (ja) | 2017-10-26 |
| KR20170072279A (ko) | 2017-06-26 |
| MX395186B (es) | 2025-03-21 |
| EP3209676A1 (en) | 2017-08-30 |
| MY195018A (en) | 2023-01-03 |
| US10238729B2 (en) | 2019-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Human papillomavirus vaccine against cervical cancer: Opportunity and challenge | |
| Abeck et al. | Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children | |
| US20110158952A1 (en) | Compositions and methods for treating human papillomavirus-mediated disease | |
| Zhang et al. | Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice | |
| JP2014506562A5 (ja) | 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用 | |
| Tsai | Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine | |
| CZ20032942A3 (cs) | Vakcína | |
| Ding et al. | Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer | |
| CN108126204A (zh) | 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法 | |
| KR102285401B1 (ko) | 암 및 피부 병변 치료 | |
| Min et al. | Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline | |
| KR102873848B1 (ko) | 백신을 사용하여 암 또는 피부 병변을 치료하기 위한 방법 및 조성물 | |
| EP2059262B1 (en) | A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein | |
| KR20020047195A (ko) | 백신 | |
| CN1935262B (zh) | 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 | |
| HK1241898A1 (en) | Cancer and skin lesion treatment | |
| Abdulsalam et al. | Role of HPV vaccines in multiple recalcitrant warts treatment | |
| JP2017531699A5 (enExample) | ||
| US20180250378A1 (en) | Combination of therapeutic vaccine and pd-1-related blockade for treating human papillomavirus-associated diseases | |
| Al-Azmi et al. | Human papillomavirus: manifestations, prevention and treatment: an overview | |
| Fruscalzo et al. | Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development | |
| Braun et al. | Elimination of human papillomavirus 16-induced tumors by a mucosal rAd5 therapeutic vaccination in a pre-clinical study | |
| Tezikov et al. | Anogenital Warts: New Opportunities for Prevention | |
| CA3145936A1 (en) | Vaccine combination and method for using the same | |
| Jorge et al. | Update: HPV prevention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170518 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201020 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20201020 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210210 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210623 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210727 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210728 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240626 Start annual number: 4 End annual number: 4 |